GLO30

GLO30 began franchising in 2022, a mere three years ago, building to just 6 franchise units alongside 4 corporate stores—a tiny footprint signaling a nascent system still proving its model. Item 7 outlines initial investments from $295,500 to $599,500, kicked off by a $45,000 franchise fee, followed by 6% royalties, 2% brand/ad fund, plus extras like a $200/month tech fee, ~$2,500/month third-party tech, up to 2% marketing, and $100/month mystery shops. System health shows modest traction: 1 transfer, no major contraction, and 16 projected new units, hinting at franchisor ambition but underscoring the risks of a small, untested network where support might stretch thin.

Item 19 shines brightly on revenues—average gross sales hit $834,225 across units—but the 0% EBITDA margin screams red alert, meaning sky-high costs devour every dime of profit before taxes, interest, etc. Estimated profits swing wildly from $152,115 to $578,758, likely reflecting top vs. bottom performers in this membership-driven model of facials, injectables, and light therapy. For investors eyeing beauty services, the high revenue potential tempts, but razor-thin (or negative) margins in a newbie brand with only 10 total locations spell high risk—scale might fix it, or it could expose flaws in the high-overhead med-spa setup. Approach with eyes wide open.